Atia Vision Announces Durable 36-Month Results from First-in-Human Study of Dynamic Shape-Changing OmniVu Lens

Data demonstrates stable refractive outcomes and continuous range of vision through three years post-implantation

Apr. 15, 2026 at 4:50am

Got story updates? Submit your updates here. ›

An abstract, ghostly X-ray image revealing the intricate internal structure of a dynamic, shape-changing intraocular lens implant, conveying the advanced nature of this medical technology.Cutting-edge intraocular lens technology aims to restore a continuous, dynamic range of vision for cataract patients without the typical trade-offs.Campbell Today

Atia Vision, Inc. announced positive 36-month results from its first-in-human clinical study of the Atia Vision™ OmniVu Lens System, a modular shape-changing intraocular lens (IOL) designed to restore a continuous, dynamic range of vision following cataract surgery. The data, presented at the 2026 ASCRS Annual Meeting, demonstrated sustained visual and refractive outcomes through 36 months post-implantation, with a favorable and stable safety profile.

Why it matters

These results represent a potential breakthrough for presbyopia-correcting IOLs, which have historically required trade-offs between visual range and long-term stability. The OmniVu Lens System's ability to provide a continuous, dynamic range of vision while maintaining predictable refractive outcomes and low complication rates over three years could set a new standard for premium cataract surgery.

The details

The prospective, multicenter, open-label study enrolled 19 subjects (29 eyes), including 10 binocular and 9 monocular implants. Key findings at 36 months include: Stable Refractive Outcomes - Mean manifest refraction spherical equivalent (MRSE) remained within ±0.50 D throughout 36 months of follow-up. Refractive cylinder also demonstrated stability over time. Strong Binocular Visual Acuity - At 36 months, mean binocular uncorrected distance visual acuity was 20/16 and mean best-corrected distance visual acuity was 20/12. Mean binocular uncorrected intermediate visual acuity was 20/20 and mean binocular uncorrected near visual acuity was 20/25, J1. Continuous Range of Focus - Binocular defocus curve testing demonstrated 20/32 or better vision over approximately 5.0 D of continuous defocus. Favorable Safety Profile - Across all eyes and all study visits, only one YAG capsulotomy procedure was performed, and no lens exchanges or refractive enhancements were required.

  • The 36-month results were presented at the 2026 ASCRS Annual Meeting.

The players

Atia Vision, Inc.

A Shifamed portfolio company developing a modular presbyopia-correcting intraocular lens to address the full range of vision for patients with cataracts and presbyopia.

William F. Wiley, M.D.

Medical Director of the Cleveland Eye Clinic and presenter of the 36-month data at the 2026 ASCRS Annual Meeting.

Mariam Maghribi

President and CEO of Atia Vision.

Got photos? Submit your photos here. ›

What they’re saying

“Surgeons have long had to accept trade-offs with presbyopia-correcting lenses. Unpredictable effective lens position, routine YAG capsulotomy, and compromised visual quality have simply been the cost of offering patients a range of vision. These 36-month data tell a very different story.”

— William F. Wiley, M.D., Medical Director of the Cleveland Eye Clinic

“These 36-month results reinforce what we set out to prove, that patients should not have to choose between continuous range of vision and long-term stability. We challenged long-held assumptions about lens design, and the durability of these outcomes validates that approach.”

— Mariam Maghribi, President and CEO of Atia Vision

What’s next

The Atia Vision™ OmniVu Lens System has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration to begin a U.S. feasibility clinical study.

The takeaway

The durable 36-month results from Atia Vision's first-in-human study of the OmniVu Lens System demonstrate the potential for a presbyopia-correcting IOL to provide patients with a continuous range of high-quality vision without the typical trade-offs, setting a new benchmark for premium cataract surgery.